

**Fax**☐ Urgent☐ Return reply requested☐ Original will be sent as confirmation

To: U.S. Patent and Trademark Office

Date: December 4, 2006

Attention: Examiner Yong Chu

Re: Appl. No. 10/538,997; Filed 02/08/06

From: Cynthia M. Bouchez, Ph.D., Esq. *CMB*For: N-(substituted arylmethyl)-4-
(disubstituted methyl) Piperidines and
PiperazinesInventors: Ding *et al.*

Pages (including cover sheet): 2

Your Reference:

Fax No: 571-273-5759

Our Reference: 2400.1070003/JMC/VLC/CMB

Message

Further to our telephone conversation today, attached please find the structure for **Compound 149** in Table 1 of the above-identified patent application.


If you have any questions or comments, please do not hesitate to contact us.

615303_1.DOC

If any portion of this transmission is not received clearly or in full,
contact us at 202.371.2600 or f 202.371.2540

This message is intended for the exclusive use of the individual or entity to which it is addressed. The message may contain information that is privileged, confidential, or otherwise exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or use of this communication in any way is strictly prohibited. If you have received this communication in error, please call us collect immediately, and return the original message to us at the above address via the U.S. Postal Service.

Sterne, Kessler, Goldstein & Fox P.L.L.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skof.com



N-[2-(1-{[4-(2-ethyl-1,2,3,4-tetraazol-5-yl)]phenyl}methyl)(4-piperidyl))-2-[4-(trifluoromethoxy)phenyl]-1-aza-vinyl][4-(trifluoromethoxy)phenyl]carboxamide